Sugi Predict

Sugi Predict / Compounds / SCHEMBL7992

SCHEMBL7992

SCHEMBL7992

CCCOc1cccc(B(O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ ENPP2 Q13822 5/20 0.59
▸ KMT2A Q03164 1/20 0.54
▸ LPL P06858 2/20 0.47
▸ LIPG Q9Y5X9 2/20 0.47
▸ TSHR P16473 1/20 0.44
▸ KAT6A Q92794 1/20 0.43
▸ ERN1 O75460 1/20 0.43
▸ NR1H4 Q96RI1 1/20 0.43
▸ KDM4E B2RXH2 2/20 0.42
▸ GPBAR1 Q8TDU6 1/20 0.42
▸ CYSLTR1 Q9Y271 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL177358 0.91 ENPP2 (0.58) ENPP2LPLLIPGTSHR
SCHEMBL8395567 0.91 ENPP2 (0.50) ENPP2KMT2ALPLLIPGKDM4E
SCHEMBL29954521 0.90 LPL (0.57) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL29953647 0.88 TSHR (0.59) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL29957212 0.88 TSHR (0.59) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL29951230 0.88 TSHR (0.59) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL3151058 0.88 TSHR (0.59) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL8553 0.85 ENPP2 (0.63) ENPP2KMT2ALPLLIPGKDM4E
SCHEMBL29951803 0.84 ENPP2 (0.50) ENPP2KMT2ALPLLIPGTSHR
SCHEMBL6586842 0.84 ENPP2 (0.62) ENPP2TSHRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8361484-B2 Polymer systems for lung volume reduction therapy AERIS THERAPEUTICS, INC. (US) 2013-01-29 — — US claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 — — US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 — — EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 — — WO claimed
US-12441716-B2 Compositions and methods for increasing muscle mass and oxidative metabolism THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-14 — — US disclosed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
EP-3952849-B1 COMPOSITIONS AND METHODS FOR INCREASING MUSCLE MASS AND OXIDATIVE METABOLISM UNIV CALIFORNIA (US) 2024-09-18 — — EP disclosed
CN-113795476-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-04-09 — — CN disclosed
CN-111465589-B Compound having fluorene skeleton and method for producing same 帝人株式会社 2024-01-05 — — CN disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
CN-116438153-A Method for producing compound having fluorene skeleton, and compound having fluorene skeleton 帝人株式会社 2023-07-14 — — CN disclosed
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2023-06-15 — — US disclosed
US-20070060573-A1 Acyltryptophanols BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-03-15 — — US disclosed
US-7091214-B2 Aryl substituted Imidazoquinolines 3M INNOVATIVE PROPERTIES CO. (US) 2006-08-15 — — US disclosed
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES 3M INNOVATIVE PROPERTIES COMPANY 2006-05-25 — — US disclosed
EP-0578054-B1 Meta-substituted six membered aromatic rings for use in liquid crystal mixtures HOECHST AG (DE) 1999-05-19 — — EP disclosed
US-5447656-A Meta-substituted aromatic compounds having six-membered rings, for use in liquid-crystal mixtures HOECHST AKTIENGESELLSCHAFT (DE) 1995-09-05 — — US disclosed
EP-0613467-A1 2-PYRIDINOL DERIVATIVES AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1994-09-07 — — EP disclosed
EP-0578054-A1 Meta-substituted six membered aromatic rings for use in liquid crystal mixtures HOECHST AKTIENGESELLSCHAFT (DE) 1994-01-12 — — EP disclosed
WO-1993010093-A1 2-PYRIDINOL DERIVATIVES AND THEIR USE AS MEDICAMENTS SMITHKLINE BEECHAM PLC (GB) 1993-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441716-B2 Compositions and methods for increasing muscle mass and oxidative metabolism CPT1B, GYS1, PYGM ENPP2 2816/4885KMT2A 3175/4885LPL 712/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB ENPP2 739/4885KMT2A 3137/4885LPL 1063/4885
US-20230181462-A1 Dynamic Covalent Hydrogels, Precursors Thereof and Uses Thereof CDC37, ILK, PTMS ENPP2 3237/4885KMT2A 2860/4885LPL 4164/4885
US-20070060573-A1 Acyltryptophanols FSHR, NPY1R, NPY2R ENPP2 13/4885KMT2A 916/4885LPL 2412/4885
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH ENPP2 854/4885KMT2A 2053/4885LPL 3998/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A ENPP2 463/4885KMT2A 3863/4885LPL 1921/4885
US-20060111387-A1 ARYL SUBSTITUTED IMIDAZOQUINOLINES IL2, IFNG, IRF3 ENPP2 1122/4885KMT2A 2761/4885LPL 3788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.